Trial Profile
Phase II Multicenter 16-Week Randomized Double Blind Placebo-Controlled Evaluation of the Efficacy, Tolerability and Safety of Memantine Hydrochloride on Enhancing the Cognitive Abilities of Adolescents and Young Adults With Down Syndrome
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Jun 2023
Price :
$35
*
At a glance
- Drugs Memantine (Primary)
- Indications Down syndrome
- Focus Therapeutic Use
- 01 Jan 2022 Primary endpoint of change from baseline to week 16 in the California Verbal Learning Test second edition short-form (CVLT-II-sf) total free recall score, has not been met, according to results published in the Lancet Neurology.
- 01 Jan 2022 Results published in the Lancet Neurology
- 24 Jul 2020 Status changed from active, no longer recruiting to completed.